- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics Announces $180 Million Private Placement
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
- Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
- Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
More ▼
Key statistics
As of last trade Spyre Therapeutics Inc (SYRE:NSQ) traded at 36.19, -24.56% below its 52-week high of 47.97, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 35.22 |
---|---|
High | 36.66 |
Low | 33.80 |
Bid | 36.05 |
Offer | 36.20 |
Previous close | 33.87 |
Average volume | 338.18k |
---|---|
Shares outstanding | 36.60m |
Free float | 31.99m |
P/E (TTM) | -- |
Market cap | 1.24bn USD |
EPS (TTM) | -75.04 USD |
Data delayed at least 15 minutes, as of May 02 2024 16:39 BST.
More ▼